Small Lymphocytic Lymphoma (SLL) Clinical Trials

9 recruiting

Small Lymphocytic Lymphoma (SLL) Trials at a Glance

11 actively recruiting trials for small lymphocytic lymphoma (sll) are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Sarasota, Denver, and Bethesda. Lead sponsors running small lymphocytic lymphoma (sll) studies include Nurix Therapeutics, Inc., H. Lee Moffitt Cancer Center and Research Institute, and Dana-Farber Cancer Institute.

Browse small lymphocytic lymphoma (sll) trials by phase

Treatments under study

About Small Lymphocytic Lymphoma (SLL) Clinical Trials

Looking for clinical trials for Small Lymphocytic Lymphoma (SLL)? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Small Lymphocytic Lymphoma (SLL) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Small Lymphocytic Lymphoma (SLL) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 2

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Nurix Therapeutics, Inc.100 enrolled20 locationsNCT07221500
Recruiting

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
H. Lee Moffitt Cancer Center and Research Institute100 enrolled1 locationNCT07030400
Recruiting
Phase 1

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)+2 more
Nurix Therapeutics, Inc.248 enrolled16 locationsNCT04830137
Recruiting
Early Phase 1

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
National Heart, Lung, and Blood Institute (NHLBI)30 enrolled1 locationNCT07428707
Recruiting

LEF1 EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A MARKER FOR DIAGNOSIS AND SURVIVAL PREDICTION

Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
IRCCS Azienda Ospedaliero-Universitaria di Bologna350 enrolled1 locationNCT07313982
Recruiting
Phase 2

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
AbbVie110 enrolled31 locationsNCT02966756
Recruiting
Phase 2

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Dana-Farber Cancer Institute45 enrolled4 locationsNCT05168930
Recruiting
Phase 2

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
The First Affiliated Hospital with Nanjing Medical University79 enrolled1 locationNCT06958705
Recruiting
Phase 2

Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma (SLL)
Massachusetts General Hospital40 enrolled2 locationsNCT06849713
Recruiting

A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company300 enrolled1 locationNCT06788639